Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data
Cristina Solomon
1
CSL Behring, Marburg, Germany
2
Department of Anesthesiology, Perioperative Medicine and General Intensive Care, Paracelsus Medical University, Salzburg, Austria
,
Albrecht Gröner
1
CSL Behring, Marburg, Germany
,
Ye Jian
3
CSL Behring, King of Prussia, Pennsylvania, USA
,
Pendrak Inna
3
CSL Behring, King of Prussia, Pennsylvania, USA
› Author AffiliationsFinancial Support: The investigation was funded by CSL Behring. Editorial assistance with manuscript preparation was provided by Meridian HealthComms and funded by CSL Behring.
Fibrinogen concentrate use as a haemostatic agent has been increasingly explored. This study evaluates spontaneous reports of potential adverse drug reactions (ADRs) that occurred during postmarketing pharmacovigilance of Haemocomplettan P/RiaSTAP, and reviews published safety data. This descriptive study analysed postmarketing safety reports recorded in the CSL Behring pharmacovigilance database from January 1986 to December 2013. A literature review of clinical studies published during the same period was performed. Commercial data indicated that 2,611,294 g of fibrinogen concentrate were distributed over the pharmacovigilance period, main-contribonding to 652,824 standard doses of 4 g each, across a range of clinical settings and indications. A total of 383 ADRs in 106 cases were reported (approximately 1 per 24,600 g or 6,200 standard doses). Events of special interest included possible hypersensitivity reactions in 20 cases (1 per 130,600 g or 32,600 doses), possible thromboembolic events in 28 cases (1 per 93,300 g or 23,300 doses), and suspected virus transmission in 21 cases (1 per 124,300 g or 31,000 doses). One virus transmission case could not be analysed due to insufficient data; for all other cases, a causal relationship was assessed as unlikely due to negative polymerase chain reaction tests and/or alternative explanations. The published literature revealed a similar safety profile. In conclusion, underreporting of ADRs is a known limitation of pharmacovigilance. However, the present assessment indicates that fibrinogen concentrate is administered across a range of indications, with few ADRs and a low thromboembolic event rate. Overall, fibrinogen concentrate showed a promising safety profile.
Institution to which work should be attributed: CSL Behring, Marburg, Germany.
Keywords
Fibrinogen -
pharmacovigilance -
safety
References
1
Blome M,
Isgro F,
Kiessling AH.
et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101-1107.
2
Charbit B,
Mandelbrot L,
Samain E.
et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 05: 266-273.
3
Karlsson M,
Ternstrom L,
Hyllner M.
et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008; 48: 2152-2158.
4
Cortet M,
Deneux-Tharaux C,
Dupont C.
et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth 2012; 108: 984-989.
5
Gerlach R,
Tolle F,
Raabe A.
et al. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33: 1618-1623.
6
Ucar HI,
Oc M,
Tok M.
et al. Preoperative fibrinogen levels as a predictor of postoperative bleeding after open heart surgery. Heart Surg Forum 2007; 10: E392-E396.
7
Levy JH,
Welsby I,
Goodnough LT.
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2013; 54: 1389-1405.
8
Solomon C,
Collis RE,
Collins PW.
Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth 2012; 109: 851-863.
9
Rourke C,
Curry N,
Khan S.
et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10: 1342-1351.
10
Hiippala ST,
Myllyla GJ,
Vahtera EM.
Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-365.
12
Khan S,
Brohi K,
Chana M.
et al. Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage. J Trauma Acute Care Surg 2014; 76: 561-568.
14
Schochl H,
Cadamuro J,
Seidl S.
et al. Hyperfibrinolysis is common in out-ofhospital cardiac arrest: results from a prospective observational thromboelastometry study. Resuscitation 2013; 84: 454-459.
15
Dirkmann D,
Radu-Berlemann J,
Gorlinger K.
et al. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid. J Trauma Acute Care Surg 2013; 74: 482-488.
18
Hunault-Berger M,
Chevallier P,
Delain M.
et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008; 93: 1488-1494.
20
Solomon C,
Wendt M.
The Factor in the License: In Reference to “Use of Prothrombin Complex Concentrates and Fibrinogen Concentrates in the Perioperative Setting: A Systematic Review”. Transfus Med Rev 2013; 28: 31.
23
Solomon C,
Pichlmaier U,
Schoechl H.
et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555-562.
26
Karlsson M,
Ternstrom L,
Hyllner M.
et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009; 102: 137-144.
27
Rahe-Meyer N,
Pichlmaier M,
Haverich A.
et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102: 785-792.
28
Rahe-Meyer N,
Solomon C,
Winterhalter M.
et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg 2009; 138: 694-702.
30
Rahe-Meyer N,
Solomon C,
Hanke A.
et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40-50.
31
Weber CF,
Gorlinger K,
Meininger D.
et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531-547.
32
Schochl H,
Nienaber U,
Hofer G.
et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55.
33
Schochl H,
Nienaber U,
Maegele M.
et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15: R83.
34
Bell SF,
Rayment R,
Collins PW.
et al. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth 2010; 19: 218-223.
35
Warmuth M,
Mad P,
Wild C.
Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand 2012; 56: 539-548.
36
Kozek-Langenecker S,
Sorensen B,
Hess JR.
et al. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15: R239.
39
Kozek-Langenecker SA,
Afshari A,
Albaladejo P.
et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30: 270-382.
40
Solomon C,
Hagl C,
Rahe-Meyer N.
Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 2013; 110: 947-956.
41
Dickneite G,
Pragst I,
Joch C.
et al. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009; 20: 535-540.
43
Danes AF,
Cuenca LG,
Bueno SR.
et al. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94: 221-226.
44
Thorarinsdottir HR,
Sigurbjornsson FT,
Hreinsson K.
et al. Effects of fibrinogen concentrate administration during severe hemorrhage. Acta Anaesthesiol Scand 2010; 54: 1077-1082.
45
Ahmed S,
Harrity C,
Johnson S.
et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage--an observational study. Transfus Med 2012; 22: 344-349.
48
Weiss G,
Lison S,
Glaser M.
et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011; 22: 727-734.
49
Kreuz W,
Meili E,
Peter-Salonen K.
et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32: 247-253.
50
Gollop ND,
Chilcott J,
Benton A.
et al. National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfus Med 2012; 22: 350-355.
53
Tanaka KA,
Egan K,
Szlam F.
et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2014; 54: 109-118.
55
Wafaisade A,
Lefering R,
Maegele M.
et al. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg 2013; 74: 387-395.
56
Groner A.
Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007; 92: 846-849 Haematologica 2008; 93: e24–27.
57
Velthove KJ,
Over J,
Abbink K.
et al. Viral safety of human plasma-derived medicinal products: impact of regulation requirements. Transfus Med Rev 2013; 27: 179-183.
60
Ni H,
Denis CV,
Subbarao S.
et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
61
Remijn JA,
Wu YP,
Ijsseldijk MJ.
et al. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb Haemost 2001; 85: 736-742.
64
O’Shaughnessy DF,
Atterbury C,
Bolton Maggs P.
et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
66
Murad MH,
Stubbs JR,
Gandhi MJ.
et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010; 50: 1370-1383.
67
Murphy GJ,
Reeves BC,
Rogers CA.
et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation 2007; 116: 2544-2552.
70
Gorlinger K,
Kozek-Langenecker SA,
Spahn DR.
Outcome criteria such as massive transfusion are inadequate for matching and result in questionable conclusions. J Trauma Acute Care Surg 2013; 75: 744-745.
71
Jacob D,
Marron B,
Ehrlich J.
et al. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf 2013; 05: 105-112.
